Sobi, Inc.
Sobi, Inc is an international biopharmaceutical company dedicated to rare diseases. Primary hemophagocytic lymphohistiocytosis (HLH) is an ultra-rare, rapidly progressive, often-fatal syndrome of hyperinflammation where hyperproduction of interferon gamma may drive immune system hyperactivation, ultimately leading to multiple organ failures. The immediate goal of treatment is to quickly control the hyperinflammation and to prepare for hematopoietic stem cell transplantation.